In day 150 of COVID-19 disease, forecasting the number of cases and deaths in Turkey COVID-19

Main Article Content

Yüksel Akay Ünvan
Oguzhan Demirel

Abstract

Objective:  This study aims to forecast the number of deaths and cases in Turkey 150 days after (6 August 2020) the first occurrence of COVID-19 in Turkey. The data used is from 10 March 2020 (the first day has seen of COVID-19 in Turkey) to 15 June 2020 and includes people of all ages from all provinces of Turkey.


Material and Method: The relationship between cases, deaths, patients in intensive care units, intubated patients, and recovered patients, which are observations of COVID-19, was examined with a correlation matrix. Afterward, the ARIMA (0,2,4) model to forecast the number of COVID-19 cases in Turkey and the ARIMA(0,3,1) model to forecast the number of COVID-19 deaths in Turkey were established.


Result: COVID-19 cases were forecasted that there may be 266.692 cases in Turkey on 6 August in the 1st model. Subsequently, a similar forecast has been made on COVID-19 deaths in Turkey on 6 August in the 2nd model. COVID-19 deaths were forecasted that there may be 5718. The p-values of these parameters of models were observed statistically significant (p<0.05). Later, the stationarity of ARIMA models related to these estimates was examined. According to the Augmented Dickey-Fuller (ADF) test results, ARIMA models were stationary and statistically convenient to use (p<0.05). Finally, the Jarque-Bera (JB) test examining the normal distribution assumption was applied and the models were found to be normally distributed.


Conclusions: Consequently, there is an increase in both predicted cases and predicted deaths by the 150th day of COVID-19. These estimates show that the number of cases and deaths will not decrease to zero level until August 6. Factors such as the biological development of the COVID-19 virus, the rate of spread of COVID-19 disease, or the presence of COVID-19 therapy may not cause any increase in these observations. On the contrary, more than expected increase may occur in observed cases.

Downloads

Download data is not yet available.

Article Details

How to Cite
ÜnvanY. A., & DemirelO. (2020). In day 150 of COVID-19 disease, forecasting the number of cases and deaths in Turkey. Medical Science and Discovery, 7(6), 535-545. https://doi.org/10.36472/msd.v7i6.394
Section
Research Article

References

1. Suzanne AA. A pest in the land: new world epidemics in a global perspective. Kindle ed. New Mexico: University of New Mexico Press; 2003.

2. Henderson D. Smallpox: the death of a disease. 1st ed. Amherst, NY: Prometheus Book; 2009.

3. Spreeuwenberg P, Kroneman M, Paget J. Reassessing the global mortality burden of the 1918 influenza pandemic. American Journal of Epidemiology. 2018;187(12):2561-7.

4. who.int [Internet]. Geneva: Naming the coronavirus disease (COVID-19) and the virus that causes it; c2020 [cited 2020 Mar 31]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it.

5. ictvonline.org [Internet]. Berlin: International Committee on Taxonomy of Viruses (ICTV); c2020 [cited 2020 Mar 31]. Available from: https://talk.ictvonline.org/.

6. Ren LL, Wang YM, Wu ZQ, Xiang ZC, Guo L, Xu T, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chinese Medical Journal. 2020;133(9):1015-24.

7. Fauci AS, Lane HC, Redfield RR. Covid-19 - navigating the uncharted 2020. The New England Journal of Medicine. 2020;382(13):1268-9.

8. cdc.gov [Internet]. Atlanta: Centers for Disease Control and Prevention. Symptoms of Coronavirus; c2019 [cited 2020 Mar 31]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html.

9. who.int [Internet]. Geneva: Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases; c2020 [cited 2020 Mar 31]. Available from: https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117.
10. Hao Q, Wu H, Wang Q. Difficulties in false negative diagnosis of coronavirus disease 2019: a case report. North Carolina: Research Square; 2020.

11. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Napoli RD. Features, evaluation and treatment coronavirus (COVID-19). Treasure Island (FL): StatPearls Publishing; 2020. https://www.ncbi.nlm.nih.gov/books/NBK554776/.

12. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research. 2020;30:269-71.

13. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases? The Lancet Infectious Diseases. 2003;3(11):722-7.

14. Yan Y, Zou Z, Sun Y, Li X, Xu KF, Wei Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza a H5N1 virus infection in an animal model. Cell Research. 2013;23(2):300-2.

15. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. BioScience Trends Advance Publication. 2020;14(1):72-3.

16. who.int [Internet]. Geneva: WHO R&D blueprint: informal consultation on prioritiza-tion of candidate therapeutic agents for use in novel coronavirus 2019 infection; c2020 [cited 2020 Apr 1]. Available from: https://apps.who.int/iris/bitstream/handle/10665/330680/WHO-HEO-RDBlueprint%28nCoV%29-2020.1-eng.pdf.

17. gisanddata.maps.arcgis.com [Internet]. Maryland: Coronavirus COVID-19 global cases by the center for systems science and engineering (CSSE); c2020 [cited 2020 June 15]. Available from: https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6.

18. worldometers.info [Internet]. Shanghai: World Population; c2020 [cited 2020 Apr 6]. Available from: https://www.worldometers.info/world-population.

19. saglik.gov.tr [Internet]. Ankara: Republic of Turkey, Ministry of Health; c2020 [cited 2020 June 15]. Available from: https://covid19.saglik.gov.tr/.

20. Horn RA, Johnson CR. Matrix analysis. 1st ed. Cambridge: Cambridge University Press; 1985.

21. Box GEP, Pierce DA. Distribution of residual autocorrelations in autoregressive integrated moving average time series models. Journal of the American Statistical Association. 1970;65(332):1509-26.

22. Ljung GM, Box GEP. On a measure of lack of fit in time series models. Biometrika. 1978; 65(2):297-303.

23. Warriyar KV, Abraham B, Variyath AM. Robustness of some portmanteau correlation tests in financial time series. American Journal of Mathematical and Management Sciences. 2016;35(1):67-76.

24. Bako H, Rusiman M, Ibrahim L, Hazel Monica M.-P. Predictive modeling of pelagic fish catch in malaysia using seasonal ARIMA models. Agriculture, Forestry and Fisheries. 2013;2(3):136-40.

25. Thomopoulos NT. Applied forecasting methods. 1st ed. New Jersey, Englewood Cliffs: Prentice-Hall; 1980.

26. Mushtaq R. Augmented dickey fuller test. SSRN Electronic Journal. 2012;1-19.

27. Dickey DA, Fuller WA. Distribution of the estimators for autoregressive time series with a unit root. Journal of The American Statistical Association. 1979;74(366):427-31.

28. Dickey DA, Fuller WA. Likelihood ratio statistics for autoregressive time series with a unit root. Econometrica: Journal of the Econometric Society. 1981;49(4):1057-72.

29. Hosseini SM, Ahmad Z, Lai YW. The role of macroeconomic variables on stock market index in china and india. International Journal of Economics and Finance. 2011;3(6):233-43.






































































30. Jarque CM, Bera AK. Efficient tests for normality, homoscedasticity and serial independence of regression residuals. Economics Letters. 1980;6:255-9.

31. Thadewald T, Büning H. Jarque-bera test and its competitors for testing normality – a power comparison. Journal of Applied Statistics. 2007;34(1):87-105.